Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company’s launch of FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous ...

Abeona Therapeutics Inc.: Abeona Therapeutics Provides Business Update Highlighting Building Momentum in ZEVASKYN Commercial Launch

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company's launch of FDA-approved ZEVASKYN (prademagene ...
Le Lézard

Atamyo Therapeutics Presents Promising Results in the First Patients Treated With Its ATA-200 Gene Therapy in the Clinical Trial Targeting LGMD-R5 Limb-girdle Muscular Dystrophy

Atamyo Therapeutics, a biotechnology company specializing in the development of next-generation gene therapies for limb-girdle muscular dystrophy (LGMD), announced at the MDA (Muscular Dystrophy ...

Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Barclays 28th Annual Global Healthcare Conference March 11, 2026 11:30 AM EDTCompany ParticipantsBassil Dahiyat - Co-Founder, ...
ALS News Today

MDA 2026: Insmed launches Phase 1 trial of INS1202 gene therapy for ALS

Insmed has launched a first-in-human Phase 1 trial testing its experimental ALS gene therapy INS1202 in people with the disease.